You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

MEDIA ADVISORY --- BIO 2001: Highlight of Events for Wednesday, June 27

7 - 8:00 a.m.
Plenary Breakfast
Ballroom 6
2001 Biotechnology Heritage Award, presented to Dr. Francis S. Collins, Director of the Human Genome Institute at NIH and Dr. J. Craig Venter, Celera Genomics Corporation. (Note: Collins and Venter will be available to the media immediately following the breakfast in room 5B.)

 

8:15 - 9:45 a.m.
Food and Ag Track Session
Upper Level, Room 2
The Global Trade Dilemma, led by Paul Drazek, President, DTB Associates, panel speakers will discuss how increasingly expensive regulations impede international trade, largely between developing countries. Speakers will review the current impacts of trade, including costs and barriers. (Note: Panelists will be available to the media immediately following the track session in room 5B.)

 

8:15 - 9:45 a.m.
CommunicationsMezzanine Level, Room 16B
Biotech in the Media - How Are We Doing?, chaired by Dan Eramian, Vice President, Communications, Biotechnology Industry Organization, a panel of reporters who cover the biotechnology industry will discuss the effectiveness of the industry in presenting itself and its case to the public with regards to the announcement of the Human Genome Project, the introduction of GMO crops and foods and the prescription drug debate, among other issues.

 

10:15 - 11:45 a.m.
Food and Ag Track Session
Upper Level, Room 2
Lack of Global Harmonization and Challenges for Developing Countries, chaired by L. Val Giddings, Vice President, Food and Agriculture, Biotechnology Industry Organization, academics from the U.S. and Africa address the impact of agricultural biotechnology for developing countries.

 

11 a.m.
Press Conference
Upper Level, Room 5B
Israeli Export Institute: The Israeli Chief Scientist of the Israeli Ministry of Trade and Compugen Ltd., will give an overview of the biotechnology industry in Israel.

 

12 - 1:45 p.m.
Plenary LuncheonBallroom 6
Naomi Judd, Grammy award-winning singer, and Alan Hobson, cancer survivor and Mt. Everest climber (Note: Judd and Hobson will be available to the media immediately following in room 5B.)

 

2- 3:30 p.m.
Industrial and Environmental Track Session
Upper Level, Room 3
Global Climate Change and Energy - Can Modern Biotechnology Provide Workable Solutions?, led by James S. McLaren, Ph.D., President, Inverizon International Inc., speakers will discuss the broad-ranging positive impacts that industrial biotechnology solutions can have on issues pertaining to our environment.

 

2- 3:30 p.m.
Policy/Ethics Track Session
UMezzanine Level, 16A
Conserving Endangered Species in the Genomics Era, this session brings scientists working at the interface of genomics and conservation from the world-famous San Diego Zoo, the biotechnology industry and the Human Genome Project to present new research findings and initiatives for benefiting endangered species. Chaired by Oliver A. Ryder, Ph.D., Kleberg Genetics Chair, Center for Reproduction of Endangered Species.

 

2 - 3:30 p.m.
Science Track Session
Upper Level, Room 9
Hitting the Target - Accurate Drug Delivery, the panel of speakers, led by Paul Drayson, Ph.D., CEO. PowerJect Pharmaceuticals plc, has been chosen to provide a broad overview of the current  state of the art  in biotech drug delivery and will provide thoughtful, provocative insights into the challenges and opportunities ahead for the industry.

 

2 - 3:30 p.m.
Science Track Session
Upper Level, Room 10
Regenerative Medicine: Sustaining Human Health by Harnessing the Body's Regenerative Capabilities, Co-chairs Doros Platika, M.D., President and CEO, Curtis, Inc. and Daniel Hartmann, Faculty of Pharmacy, will discuss how regenerative medicine seeks to harness the body's inherent ability to repair damage caused by disease, trauma or age.

 

3:30 p.m.
Press Conference
Upper Level, Room 5B

Biotechnology Industry Organization and Ardana Bioscience to Donate $30,000 Grant to World-Famous San Diego Zoo, presented to Dr. Oliver A. Ryder, Kleberg Genetics Chair, Center for Reproduction of Endangered Species, by Simon G. Best, Chief Executive Officer, Ardana Bioscience, Board of Directors, Biotechnology Industry Organization; David Robinson, Chairman, Biotechnology Industry Organization, Chairman, President and Chief Executive Officer, Ligand Pharmaceuticals, Inc.; Joe Panetta, President and Chief Executive Officer, BIOCOM/san diego and Ray Briscuso, Executive Director, Biotechnology Industry Organization.

 

4 - 5:30 p.m.
IP/Legal Track Session
Upper Level, Room 4

Global Balancing Act: Intellectual Property Rights and the Plight of the Poor, Anne G. K. Solomon, Senior Adviser and Former Deputy Assistant Secretary of State for Science, Technology and Health, will lead a discussion about intellectual property rights (IPR) protection and its importance to the vitality of technological innovation and commercialization.

 

4 - 5:30 p.m.
Policy/Ethics
Mezzanine Level, Room 16A

Cloning and Stem Cells: New Controversies, led by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, this session will examine the NIH policy to allow federal funding for research using stem cells, which is currently under review by the Bush administration.

 

4 - 5:30 p.m.
Science Track Session
Upper Level, Room 9

Innovative Research and Infectious Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research that could lead to treatments for infectious diseases such as hepatitis, herpes, malaria, HIV and the common cold.

 

2 - 3:30 p.m.
Therapeutic Devices Track Session
Mezzanine Level, Room 14A

The Future of DNA Microarrays and Bioinformatics in Research and Diagnostics, chaired by August Sick, Senior Manager, Business Development, Invitrogen Corporation, this session will present recent applications demonstrating the power of microarrays and advanced bioinformatics technologies in identifying differentially expressed biomarker genes.

 

2 - 3:30 p.m.
Policy/Ethics Session
Mezzanine Level, Room 16A

Oversight of Gene Therapy: Protecting Patients and Promoting Research
The FDA and NIH have recently formally issued plans that would dramatically change the regulatory environment for companies doing gene therapy experiments. This program, chaired by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss several important issues surrounding regulation in the industry.

 

2 - 5:30 p.m.
Finance Track Session
Upper Level, Room 11

Mergers & Acquisitions Symposium, chaired by Richard A. Leavitt, Principal, William Gallagher Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller Ehrman White & McAuliffe LLP, speakers on this panel will address the future of genomics and the information challenge it poses.

 

3 p.m.
Press Conference
Upper Level, Room 5B

Florence Wambugu, Ph.D., Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from Kenya."

 

4 p.m.
Press Conference
Upper Level, Room 5B

MediChem/Neurocrine Announcement, MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical discovery and development company, will announce that they have entered into a two-year collaborative GPCR agreement in proteomics for new drug development.

 

4 - 5:30 p.m.
Science Track Session
pper Level, Room 9

Animal, Mineral or Vegetable: Which Model for Product Discovery, John A. Ryals, Ph.D., President and CEO, Paradigm Genetics, chairs a discussion about the utility of different gene-based discovery models that have influenced the success of the genomics industry.

 

4 - 5:30 p.m.
Policy/Ethics Track Session
Mezzanine Level, Room 16A

The Impact of State Drug Price Control Schemes on Emerging Biotech Companies, Thomas C. Norton, Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion of the consequences of state drug price control programs.

 

4 - 5:30 p.m.
Therapeutic Devices Track Session
Mezzanine Level, Room 14A

Managing Diabetes: Advances in Insulin Therapy from Novel Delivery Systems, Lars Karlsen, Senior Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S, chairs a discussion of how recent advances in insulin delivery will improve patient compliance with insulin regimens and quality of life.

 

4 - 5:30 p.m.
Science Track Session
Upper Level, Room 10

Raiders of the Lost Genome: Gene Analysis on the Post-Genome Era, chaired by Teresa W. Ayers, CEO and Director, Genomica, this panel will review and discuss a variety of new technologies that will facilitate the deciphering of genetic data and provide gene function information for product development.

 

4 - 5:30 p.m.
Food and Ag Track Session
Upper Level, Room 2

Innovative Research and Infectious Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research that could lead to treatments for infectious diseases such as hepatitis, herpes, malaria, HIV and the common cold.

 

4 - 5:30 p.m.
Science Track Session
Upper Level, Room 10

Stopping Global Pandemics in the Track, chaired by Franklin Berger, Senior Analyst, JP Morgan.